Eupraxia Pharmaceuticals Stock Current Ratio
EPRXFDelisted Stock | USD 2.79 0.04 1.45% |
Eupraxia Pharmaceuticals fundamentals help investors to digest information that contributes to Eupraxia Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Eupraxia Pink Sheet. The fundamental analysis module provides a way to measure Eupraxia Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eupraxia Pharmaceuticals pink sheet.
Eupraxia |
Eupraxia Pharmaceuticals Company Current Ratio Analysis
Eupraxia Pharmaceuticals' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Eupraxia Pharmaceuticals Current Ratio | 10.13 X |
Most of Eupraxia Pharmaceuticals' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eupraxia Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
CompetitionIn accordance with the recently published financial statements, Eupraxia Pharmaceuticals has a Current Ratio of 10.13 times. This is 248.11% higher than that of the Healthcare sector and 44.71% higher than that of the Biotechnology industry. The current ratio for all United States stocks is notably lower than that of the firm.
Eupraxia Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eupraxia Pharmaceuticals' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Eupraxia Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Eupraxia Pharmaceuticals by comparing valuation metrics of similar companies.Eupraxia Pharmaceuticals is currently under evaluation in current ratio category among its peers.
Eupraxia Fundamentals
Return On Equity | -0.89 | |||
Return On Asset | -0.33 | |||
Current Valuation | 43.78 M | |||
Shares Outstanding | 21.39 M | |||
Shares Owned By Insiders | 12.40 % | |||
Shares Owned By Institutions | 20.24 % | |||
Price To Book | 3.89 X | |||
EBITDA | (21.96 M) | |||
Net Income | (22.99 M) | |||
Cash And Equivalents | 35.46 M | |||
Cash Per Share | 1.66 X | |||
Total Debt | 9.26 M | |||
Debt To Equity | 0.42 % | |||
Current Ratio | 10.13 X | |||
Book Value Per Share | 0.95 X | |||
Cash Flow From Operations | (14.64 M) | |||
Earnings Per Share | (0.98) X | |||
Number Of Employees | 19 | |||
Market Capitalization | 78.89 M | |||
Total Asset | 31.22 M | |||
Z Score | 4.8 | |||
Net Asset | 31.22 M |
About Eupraxia Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eupraxia Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eupraxia Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eupraxia Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
EBR | Centrais Electricas Brasileiras | |
HE | Hawaiian Electric Industries | |
VFC | VF Corporation | |
BVHMF | Vistry Group PLC | |
S | SentinelOne |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Other Consideration for investing in Eupraxia Pink Sheet
If you are still planning to invest in Eupraxia Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eupraxia Pharmaceuticals' history and understand the potential risks before investing.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |